Wales and NI follow England in backing Vertex CF therapies

Three of the four UK nations have agreed a long-term deal with Vertex Pharma for reimbursement of its cystic fibrosis therapies, ensuring permanent access to the drugs for eligible patients

Labour government would use compulsory licensing for expensi...

Orkambi parents start ‘buyers club’ to import generic versio...

A group of parents in the UK have taken matters into their own hands in an effort to get their children access to Orkambi, the cystic fibrosis drug at the centre of a three and a half year

Vertex’s CF drug gets label extension as pricing row continu...

While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in you

UK urges Vertex to accept 'generous' Orkambi funding offer

Vertex remains at loggerheads with NHS England over funding for Orkambi, but said it would consider the body’s most recent offer of a £500 million, five-year funding deal.

10 drugs – and their prices – which changed pharma in 2015

In a record-breaking year for pharma, which drugs were the most outstanding?